Mezigdomide
Mezigdomide, a new oral drug for multiple myeloma, shows ‘modest’ survival benefit in phase 1 trial
Anika Sharma
A new oral drug for multiple myeloma, mezigdomide, has shown a ‘modest’ survival benefit in a phase 1 trial involving ...